Table 3 Stepwise multiple regression analysis of the improvement of the BCVA.

From: Intravitreal anti-vascular endothelial growth factor monotherapy in age-related macular degeneration with submacular hemorrhage

Independent variables

Dependent variable

Improvement of the visual acuity*

Partial regression coefficient

Standard error

p value

Age

0.0058

0.0042

0.1709

Development of VH

0.6074

0.1491

 < 0.001

  1. Excluded variables: sex, type of anti-VEGF agents, taking anticoaglants, subtype of AMD, duration of symptoms, DAs, baseline BCVA, CFT, thickness of SMH, and thickness of PED.
  2. BCVA best-corrected visual acuity, VH vitreous hemorrhage, VEGF vascular endothelial growth factor, AMD age-related macualr degeneration, DAs disc areas, CFT central foveal thickness, SMH submacular hemorrhage, PED pigment epithelial detachment.
  3. *Improvement of the visual acuity = the difference between the baseline visual acuity and postinjection BCVA at 12 months.
Back to article page